Saul J Priceman

Associate Professor of Medicine and Immunology and Immune Therapeutics

Director of the KSOM/NCCC Center for Cancer Cellular Immunotherapy Research

Norman and Mary Pattiz Endowed Chair for Cancer Research

Image of Saul J Priceman
Is this your profile? Click to edit

Overview

Dr. Saul Priceman is an Associate Professor in the Department of Medicine at USC, and the Founding Director of the KSOM/Norris Center for Cancer Cellular Immunotherapy Research. Over the last 14 years, his research has focused on T cell immunobiology and cancer immunotherapies. Dr. Priceman’s laboratory develops CAR T cell therapies and combinatorial approaches for the treatment of solid cancers, bringing several therapies to phase 1 clinical testing. His research has led to high-impact publications in Nature Medicine, Nature Biomedical Engineering, Science Translational Medicine, and Nature Communications, with numerous patents and technologies licensed for further clinical development. Dr. Priceman’s research has been funded with grants from the National Cancer Institute, Department of Defense, California Institute for Regenerative Medicine, and the Prostate Cancer Foundation. He received his B.S. in microbiology at UCSB, his Ph.D. in molecular and medical pharmacology at UCLA, and his postdoctoral research at City of Hope.

Awards

  • Prostate Cancer Foundation: Young Investigator Award, 2015
  • National Comprehensive Cancer Network: Young Investigator Award, 2016

Education and Training

  • University of California Santa Barbara — BS — 2000 — Microbiology
  • California State University Northridge — MS — 2004 — Biology
  • University of California Los Angeles — PhD — 2010 — Molecular and Medical Pharmacology
  • City of Hope — Postdoctoral Fellowship — 2013 — Cancer Immunotherapy and Tumor Immunology

Research Keywords

  • Tumor immunology
  • Cancer cellular immunotherapy

Publications

  • Preclinical proof of concept for a personalized SNAP™-TIL (Specific Neo-Antigen Peptides-TIL) therapy platform. Oncoimmunology. 2026 Dec 31; 15(1):2684383.. View in PubMed
  • Radioligand therapy in combination with CAR T cells overcomes the heterogeneous immunosuppressive prostate tumor microenvironment. bioRxiv. 2026 Jul 03.. View in PubMed
  • Focal radiotherapy improves CAR T cell therapy targeting prostate cancer. bioRxiv. 2026 Jun 24.. View in PubMed
  • Endothelial AGO1 deficiency reduces breast cancer burden in mice. Angiogenesis. 2026 06 12; 29(3).. View in PubMed
  • Whole-protein screening and multi-modal profiling of antigen-specific CD4+ T cells at single-cell resolution. Nat Commun. 2026 May 12; 17(1).. View in PubMed
  • IL-12-engineered human PSMA-CAR T cells for the treatment of advanced prostate cancer. Mol Ther Adv. 2026 Jun 11; 34(2):201730.. View in PubMed
  • A class act: HDAC1- Malat1 regulates MDSC apoptosis and cell cycling to decrease suppression of T cells. bioRxiv. 2026 Mar 25.. View in PubMed
  • IL12-engineered human PSMA-CAR T cells for the treatment of advanced prostate cancer. bioRxiv. 2026 Mar 08.. View in PubMed
  • Current state of CAR-T cell therapies for solid tumors. Med. 2026 May 08; 7(5):101028.. View in PubMed
  • Intracranial metastases from solid tumors: Call to action and consensus from the Society for Neuro-Oncology and American Society of Clinical Oncology collaborative. Neuro Oncol. 2026 Feb 01; 28(2):319-333.. View in PubMed